Figure 6.
Progression‐free survival according to progression of disease after first‐line immunochemotherapy (before/after 24 mo of treatment) prior to enrollment in the trial
Progression‐free survival according to progression of disease after first‐line immunochemotherapy (before/after 24 mo of treatment) prior to enrollment in the trial